The recent announcement by the Innovation Center at the Center for Medicare and Medicaid Services regarding the launch of an Oncology Care Model is an important step toward patient-centered cancer care.
In a unanimous vote, the FDA Oncologic Drugs Advisory Committee advised the agency to accept the metric of “minimal residual disease,” or MRD, as a basis for accelerated approvals of therapies in all settings of multiple myeloma.
